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Abstract 
Cerasomes, a novel organic-inorganic nanohybrid, offer the potential to replace liposomes as a 
morphologically superior drug delivery vehicle. Due to the surface silicate network, cerasomes 
have previously demonstrated enhanced stability against membrane destabilization and lipid 
aggregation, thus improving therapeutic effectiveness. Here we use the one step, facile, coaxial 
electrospraying technique to prepare deionized water encapsulated cerasome nanoparticles. We 
have identified the parameters necessary to repeatedly produce particles of 217 ± 21 nm in size, 
PDI = 0.19 ± .05. SEM images confirmed the size measurements obtained using dynamic light 
scattering. The electric field strength was identified as a key factor in forming a stable 
electrospray process. The magnitude of the flow rate did not play a major role in affecting 
particle size. This study has demonstrated, for this first time, that loaded cerasomes can be 
successfully and repeatedly prepared using the electrospray method. Incorporating anticancer 
drug Doxorubicin HCl into the core of cerasomes is in progress. 
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Chapter I 
Introduction 
Advances in technology are creating endless possibilities for the future of drug delivery 
systems in nanomedicine. Nanoparticle carriers offer many benefits over free drug 
administration, such as controlled drug loading, release profiles, and tissue-specific 
targeting, all of which amount to a reduced organ toxicity. Research into these areas is 
continually uncovering new mechanisms for improved particle design and drug loading 
mechanisms. In addition to the use of novel carrier materials and fabrication methods, 
surface modifications add yet another way in which particles can be tailored for improved 
safety and therapeutic effect. Due to high biocompatibility and particle tailorability, 
liposomal drug delivery systems have shown the greatest success clinically. Despite this, 
liposomes suffer from having a morphologically weak phospholipid bilayer membrane 
that readily destabilizes in the presence of acids, bases, or surfactants. In addition to 
premature drug release, liposomes exhibit a tendency to aggregate and fuse together 
through amphipillic lipid exchange. Increased particle size makes them an easy target for 
body clearance systems. Both destabilization and fusion ultimately result in a reduced 
amount of drug reaching the desired location and thus a decrease in therapeutic efficacy. 
As such, liposomes remain a suitable, but limited drug delivery vehicle. 
The field of nanomedicine and drug delivery systems would greatly benefit from a 
liposome-like drug delivering nanoparticle, but with higher morphological stability. 
Recently, such a carrier was created. "Cerasomes" are a novel organic-inorganic hybrid 
consisting of a standard liposomal membrane, but with a silicate surface. It has been 
repeatedly demonstrated in several preparation and characterization studies that 
cerasomes have improved membrane stability and a slower drug release profile than 
liposomes. The only attempts at creating and drug loading cerasomes have used the 
traditional sol-gel preparation technique. While effective, this method is a lengthy, multi-
step process that produces polydisperse particles with low encapsulation efficiency and 
less than ideal drug loading capacity. Recently, coaxial electrohydrodynamic spraying 
("electrospraying") has emerged as a simple, one-step, technique for creating core-shell 
nanoparticles. Published electrospray literature has demonstrated advantages of the 
higher encapsulation efficiency and drug loading than standard methods using various 
types of shell materials. However, creation of core-shell cerasome vesicles by coaxial 
electrospraying has not been reported thus far. For the first time, this study combines the 
morphological stability of cerasomes lipids with the highly effective electrospraying 
preparation method to produce nano-sized core-shell cerasome particles. Successful 
1 
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demonstration of the ability to do so will set the stage for future cerasome drug loading 
studies using coaxial electrospraying. 
1.1 Specific Aims 
The goal of this study is demonstrate that core-shell vesicles from cerasome-forming 
organotrialkoxysilane lipids can be created using the electrospray method. Due to the 
novelty of this research, it will be necessary to experimentally identify the parameters 
that create a stable electrospray process. It is a specific aim of this study to produce 
cerasome vesicles of 100-300 nm, a range that is optimal for drug delivery vehicles. It is 
a subsequent aim for these particles to have a narrow size distribution. This will be 
defined as a polydispersity index (PDI) less than 0.2, measured using dynamic light 
scattering. Upon accomplishing these aims, it is a long range goal of this study to 
encapsulate anti-cancer drug Doxorubicin into the core of cerasome particles. For 
electrospraying to become a preferred method of producing doxorubicin loaded 
cerasomes, it will need to demonstrate higher encapsulation efficiency with higher drug 
loading content than achievable using the standard preparation techniques. Additionally, 
doxorubicin loaded cerasomes should be shown to have improved membrane stability, 
slower drug release profile, and improved therapeutic effect over PEGylated liposomal 
doxorubicin. The drug loading and release studies are areas for future investigation. 
1.2 Drug Delivery Systems 
Drug delivery systems (DDS) are a method or process of administering a pharmaceutical 
compound to achieve a therapeutic effect. The therapeutic index is the margin between 
doses resulting in therapeutic efficacy (i.e. tumor cell death) and toxicity to other organs 
[ 13]. Drug delivery systems are used to increase the therapeutic index of a 
pharmaceutical compound in several ways; 
(1) Carrier systems isolate the drug from the aggressive environment of the body. 
Varying pH or temperature conditions can degrade the drug, alter its structure, or 
render it biologically inactive. Protection from the in vivo environment ensures 
that the correct form of the drug and intended dosage reach the target location. 
(2) Carriers can be modified and tailored for specific tissue targeting. Through this, 
DDS not only reduce toxicity to other organs, but they allow for a higher dosage 
of drug to be administered [ 6]. 
(3) Carrier systems increase circulation time. Free drugs generally have shorter half 
lives than drug loaded carriers because carriers can be formulation to avoid body 
clearance by the reticuloendothelium system (RES) or glomerular filtration. The 
RES is characterized by mononuclear phagocytic entrapment in the liver and 
spleen. In theory, prolonged circulation increases the probability that the carrier 
systems will reach the desired or targeted location [9]. 
2 
( 
( 
' ( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
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(4) DDS are more effective than free drug in that they can be modified to have 
optimal absorption, distribution, and drug release profiles. In general, the higher 
the drug loading ratio of drug/lipid (wt./wt.%) and the slower the release profile, 
the more effective the treatment becomes [12]. 
Together, these four aspects of DDS greatly improve the efficacy of a treatment. 
Important Characteristics for Drug Delivery Systems 
3 
Drug delivering systems, in the context of nanomedicine, consist of at least two 
components; one of which is the pharmaceutically active ingredient, the other a non-toxic 
carrier vehicle. By definition, drug delivering nanoparticles are in the range of 10-1000 
nm. It is generally accepted that the primary goals for research in nano-bio-technologies 
of drug delivery include; more specific drug targeting and delivery, reduction in toxicity 
while maintaining therapeutic effects, greater safety and biocompatibility, and faster 
development of new safe medicines [ 13]. 
There are four critical parameters to consider when formulation a new drug delivery 
system; size, drug loading, encapsulation efficiency, and release profile. Size is a key 
factor in circulation time and in the biodistribution of circulating carriers, both of which 
factor into therapeutic efficacy. Drug loading, described as the drug/lipid ratio, tells how 
much drug is encapsulated per vesicle. This has affects in overall dosage, which relates 
to both toxicity and overall therapeutic efficacy. Higher Encapsulation efficiency is 
directly linked to the commercial viability because of reduction of waste of costly 
pharmaceuticals. As for release profile, the drug-loaded vesicle must exhibit drug release 
rates that are conducive to improvements in drug activity through decreases in toxicity or 
increases in efficacy. Fast release rates are as ineffective as free drug, but slow release 
rates may not deliver enough of the drug to have therapeutic value [18]. 
Ideal Drug Delivery Vehicle 
N anoparticles have emerged as the leading candidate for drug delivery systems in 
nanomedicine. At the appropriate size (100-300 nm), nanoparticles can be formulated to 
evade bodily clearance, promote cellular endocytosis by target tissues, and release their 
contents directly at the desired site. They have high surface:mass ratios, which provide a 
sizable platform for surface modifications or drug coating [13]. When created with a 
hollow core, the drugs, probes, proteins, or genes to be delivered can be encapsulated 
inside the particle for protection of the compound and/or reduction of toxicity to the 
body. Nanoparticles carriers can be made from a variety of materials, and depending on 
this, bear certain advantages or disadvantages for particular applications. Biological 
types, such as lipids (phospholipids), proteins, carbohydrates (dextran, chitosan, or 
gelatin) have advantage ofbiocompatibility and reduced toxicity, but often suffer from 
weak morphologies/structures. Polymers have fairly good biocompatibility with a major 
advantage in "tailorability" to control circulation time, degradation and drug release. 
Both biological and polymer types have been greatly explored as carriers in drug delivery 
applications. Metallic particles such as silver, iron, gold, platinum, etc., typically suffer 
from being the least biocompatible, and pose the greatest concern for bodily clearance 
CHAPTER 1. INTRODUCTION 4 
and toxicity. Metallic particles are often utilized as contrast agents for imaging, and 
recently in tumor thermal ablation treatments. Certain metallic particles, due to magnetic 
properties, can also be utilized for site-specific targeting. 
1.8 Liposomal Drug Carriers 
1.3.1 Liposomes 
Liposomes are artificially prepared vesicles made of a phospholipid bilayer. They were 
first created in 1961 by Dr. Alec Bangham using what is today known as the "Bangham 
method." Liposomes are amphiphilic, consisting of a hydrophilic head group and 
hydrophobic hydrocarbon chain tail [25]. See Figure 1.1. 
Figure 1.1: Phospholipid Liposome Vesicle [ 15] 
In polar, aqueous solutions such as water, these phospholipids spontaneously align into 
spherical bilayers with the polar head groups in contact with the solution. Both the outer 
surface of the sphere and inner lining of the hollow core are hydrophilic surfaces. The 
region between these surfaces, where the carbon tails align side-by-side, constitutes the 
hydrophobic region. Depending on the preparation method, liposomes can exist in two 
main forms; unilamellar and multilamellar vesicles. Multilamellar vesicles (ML V) form 
spontaneously in hydrophilic solutions (Figure 1.2). Unilamellar vesicles, both small 
(SUV, 20-100 nm) and large (LUV, > 100 nm), require high shear rate sonication ( or 
other post-processing methods) to reduce the multiple layers into a single bilayer 
membrane [28]. 
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CHAPTER 1. INTRODUCTION 
Puri et al [2009], there are 7 FDA-approved liposomal drugs, with 8 more in clinical 
trials. See Appendix A for a list of these products. 
1.3.3 Liposomal Doxorubicin 
7 
A long range goal of this study is to encapsulate doxorubicin into cerasomes and 
demonstrate higher drug loading content, improved membrane stability, slower drug 
release, and higher encapsulation efficiency than is currently achieved with liposomal 
formulations. Doxorubicin was chosen for this study because it is the best known and 
most widely used anthracycline antibiotic for cancer therapy. It was first introduced in 
the 1970's and since then has become one of the most commonly used drugs for the 
treatment of hematological and solid tumors [18]. Due to its extreme toxicity to tissues, 
doxorubicin must be administered intravenously. Even so, damage to organs, particularly 
the heart, has limited its dosage. An approach to alleviating doxorubicin' s toxicity is to 
use drug carriers. The advantageous properties of liposomes ( as previously described) 
have led to their emergence as the top choice pharmaceutical carrier. In November, 
1995, the FDA approved liposomal doxorubicin hydrochloride (trade name Doxil), for 
the first-line treatment of advanced AIDS-related Kaposi's sarcoma disease that has 
progressed in spite of prior combination chemotherapy, or in patients intolerant of such 
combination therapy [19]. Doxorubicin is an anthracycline antibiotic originally isolated 
from Streptomyces peucetius var. caesius. It works as an anti-tumor agent because it 
intercalates between the DNA strands, inhibiting topoisomerase II activity and inducing 
tumor cell DNA fragmentation. Additionally, liposomal doxorubicin induces expression 
of monocyte chemoattractant protein- I, resulting in intralesional recruitment of 
phagocytic cells in patients with KS [19]. As the first approved, most established and 
successful liposomal drug, Doxil serves as a model drug delivery system to learn from 
and aim at improving upon. 
The primary aim of doxorubicin encapsulation in liposomes has been to decrease 
nonspecific organ toxicity. Liposomes are able to direct the doxorubicin away from sites 
with tight capillary junctions, such as the heart muscle. Instead, they distribute in areas 
where fenestrations or gaps exist in the vasculature (liver, spleen, and bone marrow, areas 
of inflammation, and tumor tissue). By adjusting lipid concentration and incorporating 
PEG-modified lipids, liposomal doxorubicin has been able to increase circulation times 
drastically. Increased circulation time subsequently allows more time for extravasation 
across the leaky endothelium of solid tumors, and thus an improved therapeutic effect 
[18]. Table 1.2, reproduced from Maurer et al. [2001], shows the advantage of using 
drug delivery vehicles (liposomal formulations of doxorubicin) over free drug. 
CHAPTER 1. INTRODUCTION 
Fom1Jlation/trade name Dosecmwml) Plasma AUC l(mfll).111 Vd{I} Cearance 111111 TA'(l'!Jlg) 
Free doxorubidna 25 1 254 45.3 0.8 
EPC/chd (55 45,'MyocetTM> 25 19.7 18.8 23.3 n.d. 
HSPC/cholJPEG-OSPE (56:39:5)1 25 609 4.1 0.08 7.7 
Doxil®" 
Plasma AUC: Area under the plasma clearance curve; TA: Tumour accumulation; V d Volume of distribution 
Table 1.2: Pharmacokinetic parameters and tumour accumulation of different 
liposomal doxorubicin formulations in humans in comparison to the 
drug in free form. [20] 
8 
Polyethylene glycol (PEG) is the most commonly used surface modification for both 
inhibiting recognition by the reticuloendothelial system and preventing agglomeration 
with other liposomes [13]. Both of these work to improve circulation time. The 
inclusion of PEGylated lipids in liposomes was one of the two most important milestones 
that lead to the research and development of clinically suitable liposomal formulations. 
The other involved an advanced method for significantly improving drug loading 
efficiency [15]. Since the FDA's approval ofDoxil in 1995, PEGlyated liposomes have 
become the standardized way of preparing liposomes in both laboratory research and 
clinical applications. A 55:40:5 (lipid:cholesterol:PEG modified 
phosphatidylethanolamine) molar ratio is a standard preparation formula. 
Doxil (United States) and Myocet are currently the only two liposomal doxorubicin 
formulations to receive clinical approval. The major difference between Doxil and 
Myocet is that Doxil is composed of hydrogenated soya phosphatidylcholine, cholesterol 
(Chol) and PEG-modified phosphatidylethanolamine (55:40:5 molar ratio). Myocet is 
composed of egg phosphatidylcholine (EPC) and Chol (55:45 molar ratio). The EPC-
Cholesterol formulation tends to release drug approximately three times faster than Doxil, 
and has a shorter circulation time. Doxil's prolonged circulation time, due in part to the 
inclusion of PEG, has lead to improved efficacy of the treatment. On occasion, however, 
the longer circulation time has been associated with toxicities to the skin, known as 
Hand-Foot Syndrome [18]. In addition, the presence oflarge molecules of PEG on the 
liposomal surface may reduce interactions of liposomes with cells and hinder entry of 
liposomes into the tumor tissue, thereby reducing the accumulation of liposomal drug at 
the tumor site [12]. Although PEG has effects in reducing fusion, it does not completely 
eliminate it [ 15]. Therefore, despite Doxil' s success, there remains a need for a stable, 
long circulating liposomal-like vesicle free of a PEGylated surface. Cerasomes, because 
of their surface siloxane network, may fill this void. 
1.3.4 Limitations of Standard Liposomal Preparation Methods 
One of the major issues in liposome production is the lack of a simple and effective 
preparation method. As previously mentioned, there a several different methods for 
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CHAPTER 1. INTRODUCTION 
producing liposomes, yet no single method has emerged as the ideal way to prepare and 
encapsulate drug within them. The major limitations of standard technologies include 
polydisperse size distribution, low loading content and low encapsulation efficiency of 
the drug/gene. Moreover, improvement in these areas requires the use of additional 
lengthy and often complicated procedures. 
9 
The Bangham, also known as the "film method" or "sol-gel" technique, is the most 
commonly used method to prepare liposome vesicles. It is a fairly simple, but multi-step 
and lengthy process. First, the liposome solution is prepared by weighing out and mixing 
the lipid and cholesterol (and often PEG) into a glass test tube at molar ratio of 55:45 
(OR 55:40:5 with PEG). Next, it is dissolved in organic solvent, i.e. chloroform, 
methylene chloride, or a chloroform-methanol solution (95:5 v/v). High performance 
liquid chromatograph (HPLC) grade solvents should be used to avoid contamination by 
impurities [ 18]. The solvent must then be removed to create a thin lipid film. It is 
advantageous to slowly evaporate the bulk of the solvent with a stream of nitrogen gas at 
a constant temperature of 37-45°C until a thick viscous lipid slurry remains. This is 
followed by a quick transfer to a vacuum pump (or rotary evaporator), where the sample 
remains under a pressure for several hours to ensure the removal of residual solvent. The 
dry thin film is then hydrated with the solute to be encapsulated. The lipid sample is 
intermittently vortexed during the hydration process to ensure maximal hydration and 
encapsulation. The resulting multilamellar vesicles (ML Vs) are very heterogeneous and 
range from 500 nm to several micrometers in size. Because these sizes are both too large 
and too disperse to employ directly as carrier vehicles, additional processing is required 
to form smaller, unilamellar, and monodisperse vesicles. This is commonly done using 
either extrusion or ultrasonication post-processing [18]. 
There are several limitations or disadvantages to using the Bangham method. First, the 
use of an organic solvent can be troublesome. When removing the solvent, it is important 
that it be uniformly removed to prevent certain lipid components from crystallizing, 
leading to a less homogeneous lipid mixture. In addition, care must be taken in removing 
chloroform-methanol solvent mixtures from cholesterol-containing formulations. As the 
solvent is being evaporated, the cholesterol can precipitate in alcohols, leading to 
cholesterol microcrystals that will not incorporate well into the lipid bilayer after 
hydration. Cholesterol precipitates can also block the polycarbonate filters during the 
post-processing extrusion process. Aside from issues related to the rate of evaporation, it 
is extremely important that all of the organic solvent be evaporated. Any residual solvent 
has the potential to intercalate within the lipid bilayer and disrupt the ability to form 
stable vesicles [18]. Moreover, residual solvent may be toxic in vivo, limiting their use 
as drug delivery vehicles. 
Another disadvantage is that the Bangham method generally results in low encapsulation 
efficiency and distribution of the core solution within the shell. Typically, passive 
trapping methods, like the one described above, do not have high encapsulation 
efficiencies (maximum of 80%). The maximum drug-to-lipid ratio achievable is also low 
CHAPTER 1. INTRODUCTION 10 
and dependent on the drugs solubility. Additionally, passive encapsulation methods 
require removal of the unencapsulated drug. Although this can be accomplished easily in 
a laboratory setting, the methods for passive encapsulation are not well suited to scaled 
production of pharmaceutical batches for use in clinical trials. As such, only active drug 
loading procedures are used to prepare liposomal doxorubicin formulations approved for 
clinical use. There are four principal stages involved in the preparation of clinically used 
liposomal doxorubicin: 
(1) preparation of the MLVs 
(2) conversion ofMLVs to SUVs 
(3) establishment of an ion ( or pH) gradient 
(4) encapsulation of doxorubicin 
The key difference between passive and active trapping is the establishment of an ion 
gradient. The advantages with this are that drug/lipid ratios as high as 0.3/1 (wt/wt) can 
be achieved, and it can be used with any lipid composition that is able to form a bilayer 
and maintain a transmembrane ion gradient. The limitation of active loading is that it 
adds complicated and lengthy steps to the creation process. 
Using freeze/thaw cycles within the passive loading method can improve drug loading, 
but this involves incorporating extra steps into the preparation process. Mayer et al. 
(1985) documented that upon hydration of the lipid film, the buffer solute does not 
equally distribute between the aqueous core of the liposome and the outside buffer. 
Cyclic dehydration and rehydration of the ML V lipid head groups are thought to assist in 
increasing the aqueous trapped volume without changing the overall vesicle size 
distribution. The freeze and thaw method, in general, allows efficient distribution of 
solute [18]. Upon the completion of this stage, the frozen MLVs can be either stored in a 
freezer or can be carried on to the next step. Since the Baugham process creates large, 
multilamellar vesicles, post-processing techniques (i.e. extrusion or ultrasonication) are 
still necessary to create small, unilamellar vesicles. 
Reverse phase evaporation is similar in concept to the Baugham method, but is a longer 
and more complicated process. This method is more efficient than the Baugham "film" 
method because it creates unilamellar vesicles (as opposed to multilamellar) with fairly 
high encapsulation efficiency. One major drawback is that it is again long, multistep 
process that requires a complex apparatus [21]. Additionally, the particles often require 
post-processing size reduction, just like the Baugham method. Again, any process that 
uses organic solvents, removed by evaporation, run the risk of traces remaining in the 
final formulation that can be both damaging to particle stability and human health (if used 
in vivo). 
Post-processing Methods for Size and Layer Reduction 
Ultrasonication is a process by which an aqueous dispersion of phospholipids are placed 
in a strong bath sonicator and subject to high pressure sound waves, as a way to reduce 
their size and layers. The resultant liposomal particles formed are usually small 
unilameller vesicles (SUVs) of25-80 nm [23]. The problems with using this method are 
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the polydisperse size distribution and production of particles too small to be effective 
drug carriers. Particles below 100 nm have a reduced core volume and are at higher risk 
of glomerular filtration. The optimal size drug vehicle is between 100-300 nm, based on 
drug loading capacity and biodistribution properties [24]. Ultrasonication is also limited 
in terms of what can be loaded in the core. Certain proteins, drugs, or genes may become 
damaged or inactive because of the aggressive nature of the high shear forces created by 
the ultrasound waves. 
Extrusion is another method used to reduce the size, layers, and polydispersity of 
liposomal particles into monodisperse, small, unilamellar vesicles. In this, the liposomes 
are extruded under pressure through polycarbonate filters with defined pore sizes to 
generate a homogeneous population of smaller vesicles with a mean diameter that reflects 
that of the filter pore [25]. This method is also effective, but suffers from the habitual 
clogging of pores. A major downfall is that extruders are expensive and potentially 
dangerous machines that should only be operated by trained individuals. 
Since none of the preparation methods described are an ideal choice for preparing 
liposomal structures, there is no sense in using these limited technologies for the 
production of a better cerasome drug vehicle. It would be advantageous to synthesize 
core-shell cerasome particles with a device capable of high encapsulation efficiency, high 
loading levels, uniform drug distribution in the core, and without high shearing forces or 
residual solvent issues. Additionally, it should be easy to use and scalable for high output 
[14]. Electrohydrodynamic spraying, discussed in detail in section 1.5, is well-suited to 
address these issues. 
1.4. Cerasome 
1.4.1 Background 
Cerasomes have been labeled as novel organic-inorganic nanohybrids because they 
consist of an inorganic triethoxysilyl head moiety and an organic hydrophobic double-
chain segment, covalently linked with stable Si-C bonds (2, Figure 1.4) [4]. These lipid 
organotrialkoxysilanes (1, Figure 1.4) are synthesized by simple condensation reactions 
between the three molecular units, dihexadecyamine, succinic anhydride, and 3-
aminopropyltriethoxylsilane. The sol-gel/self-assembly is one of the most commonly 
used techniques to prepare hybrid materials, and has been the standard method for 
cerasome production. Using the sol-gel process (3, Figure 1.4), hydrolysis of the 
triethoxysilyl group converts the proamphiphile into an amphiphilic lipid. The structure is 
then capable of self-assembling into a liposome-like bilayer vesicle, known as a cerasome 
[4]. 
CHAPTER 1. INTRODUCTION 
cerasome 
inorganic silicate 
,----~~~-.... framework 
Figure 1.4: Cerasome Vesicle 
12 
Hydrolysis of the proamphiphilic compound into a bilayer forming amphiphil is a tightly 
regulated acid catalyzed reaction. Under acidic conditions, hydrolysis of the 
triethoxysilyl group precedes equally for each of the molecules in a one-by-one manner 
[4], providing a suitable condition for the preparation of the bilayer assembly. Under 
basic conditions, particular molecules are preferentially hydrolyzed while other 
molecules remain unreacted. Because this leads to heterogeneous hydrolysis and various 
reaction stages of the lipid molecule, basic conditions have been identified as unsuitable 
for the preparation of cerasomes. According to Katagiri et al. [2007], the conversion into 
amphiphilic form does not occur at neutral pH, even after vortex mixing in aqueous 
media. This, they claim, is likely due to the extremely slow hydrolysis of the head group. 
Furthermore, the level of acidity factors into the successful hydrolysis of the cerasome 
head groups. Under very strong acidic condition (pH 1 ), a stable dispersion is not 
obtained and precipitation is observed immediately. In this case, the hydrolysis and 
condensation reaction were so fast that vesicular structures could not form. The acid 
catalyzed hydrolytic conversion from proamphiphil to amphiphil begins to proceed at 
pH2, yielding a well packed amphiphilic monolayer. At moderately acidic conditions of 
pH 3, a translucent solution characteristic of a liposomal dispersion is obtained [ 4]. 
Based on the study by Katagiri et al. [2007], it was concluded that pH 3 provides the 
optimal environment for cerasome formation using the sol-gel process. Figure 1.5 shows 
the time course for cerasome formation as evaluated from the hydrolysis of the lipids. 
According to this figure, it takes a minimum of 10 hours (at pH 3) to fully hydrolyze. 
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This data provides support for the decision to use pH3 acid ethanol to hydrolyze the 
lipids in our electrospray study. 
100 
80 
#-
-,:: 80 2 
i 40 
0 
u 
20 
2 4 6 8 10 12 
tlh 
Figure 1.5: Time courses for the cerasome formation process as evaluated 
from the hydrolysis of the lipids (1.0 mmol dm3) in D2O at pD 3 and 
2s 0 c [4] 
13 
Katagiri et al. was the first group to thoroughly characterize and document the properties 
of cerasome particles (Figure 1.6). In their study, they utilize the standard sol-gel/self-
assembly process (followed by a short ultrasonication exposure) to create 150-300 nm. 
The following table presents the characteristic vesicle parameters for the cerasomes 
prepared. "Cerasome 1" in this figure is prepared from the same organotrialkoxysilane 
lipid used in our electrospray study. 
Parameter entity Cerasome of C,erasome of 
1 2 
available pH region for preparation around 3 2-12 
reaction time, for hydrolysis at pH 3 h 10 2 
phase transition temperaturelaJ/°C 10.5 25.7 
phase transition enthalpy changel•lJ 47.5 33.3 
kJmo1-1 
hydrodynamic diameterfbl/nm 214 30 
isoelectric pointlbl 4.3 12.0 
[a] Aqueous dispersion state. [b] Ultrasonicated sample with a probe-
type sonicator for 10 min at 30 W. 
Figure 1.6: Cerasome Characterization by Katagiri et al. [2007] 
Katagiri et al. also examine the pH dependence of zeta potential (Figure 1. 7). According 
to their findings, cerasomes have an isoelectric point (IEP) of 4.3. Since IEP is the pH at 
which a particle carriers a neutral surface charge, this means cerasomes have a large 
negative surface charge (polyanionic) under neutral and basic conditions. 
CHAPTER 1. INTRODUCTION 14 
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Figure 1.7: Cerasome zeta-potential vs. pH, by Katagiri et al. [2007] 
Zeta potential is defined as the potential difference between the dispersion medium and 
the stationary layer of fluid attached to the dispersed particles [29]. It is significant in 
that its value can be related to the stability of colloidal dispersion by indicating the degree 
of repulsion between adjacent, similarly charged particles. Figure 1.8 shows that a high 
zeta potential confers stability, whereas a low zeta potential confers a tendency of the 
dispersion to aggregate. 
Zeta potential (mV) Stability behavior of Che colloid 
from Oto ::t:5, Rapid coagulation or locculatioo 
from :t:10 to :l:30 Incipient instability 
from %30 to ±40 Moderate stability 
fromt40to:t.60 Good stability 
more than ±61 Excellent stability 
Figure 1.8: Zeta potential and colloid stability [29] 
According to Figure 1. 7, cerasomes exhibit a zeta potential between + 10 m V @ pH 3 and 
-70 m V @ pH 9 [ 1]. At neutral pH, cerasomes have a -56 m V zeta potential, indicating 
"good stability." This has excellent implications for the use of cerasomes as intravenous 
drug delivery carriers. Since the human blood is slightly alkaline (pH: 7-8), cerasomes 
would exhibit excellent stability. 
Another benefit of using cerasome drug delivery vehicles is that they have a 
hydrodynamic diameter of 214 nm [ 4]. This fits perfectly in the range of sizes that can 
best avoid glomerular filtration, and RES uptake, but favor accumulate in tumor 
vasculature. In addition to measuring overall size, Katagiri et al. also measure the 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
{ 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
{ 
l 
( 
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unilaminar thickness of Si-Lipid bilayer to be approx 4 nm. Assuming 200 nm diameter 
particles, only 8 nm of shell means that these particles have a large hollow core suitable 
for significant drug loading. 
Cerasomes show remarkably high morphological stability because of their surface 
siloxane networks, compared to weakly aligned phospholipid head groups of standard 
liposomes. In several studies, cerasomes have been shown to maintain their vesicular 
structure in the presence of membrane-solubilizing surfactants, such as Triton X-100 or 
ethanol. Typically, liposomes formed from unpolymerized phospholipids disassemble 
within 2-3 equivalents of TX-100 [1]. Note, one equivalent corresponds to a molar ratio 
of TX-100 to lipid of one to one. In a study by Katagiri and Caruso [2004], cerasomes 
remained stable passed 30 equivalents ofTX-100 [1]. The later work ofKatagiri et al. 
[2007] showed that upon 24 hours of incubation, cerasomes were stable in the presence 
of 36 equivalents (Figure 1.9). 
[TX-100] I !lipid] 
Figure 1.9: Light scattering intensities of the cerasomes and DMPC-liposome as a 
function of added equivalents ofTX-100 at 25°C: cerasome of 1 
incubated for 24 h ( closed circle); cerasome as-prepared from 1, but 
non-incubated (open circle); DMPC-liposome (open triangle). 
To provide more evidence for the advantage of cerasomes over liposomal drug vehicles, 
Cao et al. [201 0] compared the drug release profile of cerasomes and liposomes with free 
drug (Figure 1.10). Here they show that cerasomes exhibit a slower drug release profile 
than liposomes. Free paclitaxel drug release was complete within only 10 hours. 
Paclitaxel loaded liposomes (PLL) had complete release by 70 hours. Paclitaxel loaded 
cerasomes (PLC) only released 58.2% within 120 hours. This is attributed to the 
formation of siloxane bonds, which result in a silica-like surface of cerasomes with a high 
degree of polymerization. It is believed that the siloxane networks block drug release 
channels and slow the rate of release. This slower drug release is beneficial for drug 
carriers so that the treatment can be administered less often and remains active for a 
CHAPTER 1. INTRODUCTION 16 
longer period of time. A drug release profile could be too slow, but the siloxane network 
is not so highly developed for this to happen [12]. 
. . . . ~ ~ 
Titnefflollr'I 
Figure 1.10: In vitro release of paclitaxel from free PTX, PLLs, and PLCs into a 
release medium containing 0.1 % (v/v) of Tween 80 at 37 °C. Cao et 
al. [2010] 
In addition to drug release studies, Cao et al. also test the long term stability of cerasomes 
in storage at 4 °C. It was found that after two months in a hydrated state, cerasomes 
retained 88% initial drug, whereas liposomes only retained only 45%. These results 
provide further evidence for the advantage of a siloxane network in improving membrane 
stability. 
This section reviews the work of several published cerasome preparation and 
characterization studies to provide evidence and support for the notion that cerasomes are 
a promising new drug system. For reasons of optimal size, excellent stability in neutral 
pH conditions, strong resistance against destabilizing agents ( acids, bases, ethanol, TX-
I 00), long storage stability, and a prolonged drug release profile, cerasomes are superior 
drug delivery vehicles than liposomes. However, despite being a promising new 
alternative to liposomes, there is still no ideal method for preparing cerasomes. 
' ( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
( 
CHAPTER 1. INTRODUCTION 17 
1.4.2 Cerasome Preparation Methods 
To date, cerasomes have only been prepared using the standard sol-gel condensation/self-
assembly method [4]. Hydrolysis of the alkoxysilyl part of the Si-lipid is performed 
using pH 3 acid ethanol solution. The standard molar ratio of this solution, which is also 
used in several cerasome studies is 1 :200: 19:0.03 (Si-lipid:ethanol:H2O:HC1) [1, 4, 11]. 
Incubation with vortex mixing for 12 hours at 25 C was identified as optimal for vesicle 
formation [4]. An additional 24 hour incubation time of the cerasome dispersion at room 
temperature is suggested to allow for complete surface siloxane network development 
(Equation 1.1) prior to use in any experiments [11, 12]. 
Si-OCH2CH3 + H2O -+ Si-OH+ CH3CH2OH, followed by 
2Si-OH -+ Si-O-Si + H2O 
Equation I.I: Cerasome siloxane network formation [12] 
Formation of siloxane network can be confirmed with FT-IR spectroscopy. A stretching 
band assigned to the Si-O-Si group was observed around 1100 cm·1 in FT-IR 
measurements. The detectible species of the lipid oligomers have been evaluated using 
MALD-TOF-MS spectra. 
Despite the significantly higher morphological stability against collapse or fusion with 
other vesicles, it has been noticed that the polydispersity of cerasomes ( created using 
standard sol-gel methods) is quite broad. Sizes ranging from below 100 nm to several 
micrometers have been reported [1], which could potentially limit their use in some 
applications, such as drug delivery systems. In an effort to better control size and 
distribution, Katagiri and Caruso [2004] deposited Si-lipid membranes onto 
polyelectrolyte coated polystyrene solid particles to act as size templates. Upon 
successful formation of the lipid bilayer, the core was removed, leaving monodisperse 
cerasome particles. While effective, this process was a much lengthier and more 
complicated procedure than standard sol-gel. Preparation of cerasomes would greatly 
benefit from a much simpler method that can produce small particles (100-300 nm) with 
a narrow size distribution (<0.2 PDI), yet is also capable of high drug loading and 
encapsulation efficiency. 
1.4 . .3 Cerasome Drug Loading 
Several publications demonstrate the preparation and characterization of cerasome 
vesicles, but few go as far as loading them with pharmaceuticals. Cao et al. [2010], for 
the first time, created paclitaxel loaded cerasomes and compared the release profile and 
morphological stability to that of conventional PEGylated liposomes. Hydrophobic drug 
Paclitaxel was loaded into cerasomes according to the Bangham method in combination 
with sol-gel and self-assembly process. Loaded cerasomes (205.2 ±28.6 nm) had a size 
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reaching the target, and dried particles can be collection [8]. The two most important 
parameters involved in obtaining a stable Taylor are cone are flow rate of the solutions 
and strength of the electric field ( created by an applied voltage). 
1.5.1 Important Parameters 
19 
Electrospraying evolved from the process of electrospinning, a technique used to create a 
thin mat of fibers for scaffolds applicable in tissue engineering. Despite a nearly 
identical apparatus, electrospraying (into particles) is made possible through the 
adjustment of various parameters, namely flow rate and applied voltage. There is a 
specific range of voltages and flow rates where electrospraying is stable (i.e. structured 
Taylor cone) [14], which directly depends on the physical properties of the liquids being 
sprayed (i.e. conductivity, viscosity and surface tension) [6]. Of these, viscosity is the 
biggest player in going from thread ( electrospinning) to droplet ( electrospraying) 
formation [7]. As viscosity increases, it is thought to directly increase resistance of the 
solution to be separated into droplets, so it is therefore more likely to draw into a micro-
thread than spray [8]. 
In addition to viscosity, solution conductivity is an important factor in permitting the 
electrospray process. To obtain a structured Taylor cone, the electrohydrodynamic forces 
(EHD) must act on at least one of the liquids. Any liquid without conductivity cannot be 
sprayed on its own, because the lack of surface charge density prevents formation of a 
steady Taylor cone [6]. The only way insulator-type materials can be electrosprayed is 
by artificially increasing their electrical conductivity via additives. Zhang and Kawakami 
[2010] electrosprayed solid chitosan particles and concluded that by decreasing solution 
conductivity, particle size increases. Xie and Wang [2007] arrived at the same 
conclusion when electrospraying PLGA to encapsulate BSA. Therefore, it appears 
consistent that by increasing conductivity and/or decreasing viscosity, particle size can be 
reduced [8]. Flow rate is universally mentioned as an important parameter in controlling 
size. Specifically, size will increase or decrease proportionally with flow rate. Other 
studies [9, 14] have not only verified this, but consider flow rate to be the dominant factor 
in determining particle size. For droplets emitted from a stable Taylor cone, Chakraborty 
et al.[2009] describe the following relationship between various parameters and particle 
size: 
Equation 1.2: Electrospray parameters on particle diameter 
Where d: droplet diameter, Q: volume flow rate, E0 : permittivity of free space, p1 : liquid 
density, cr1 : liquid surface tension, y1 : liquid bulk conductivity, and a: a coefficient 
depending on liquid permittivity. 
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To summarize the major parameters and their effective on droplet size; a reduction in 
particle size can be achieved be a decreasing flow rate, decreasing viscosity, and/or 
increasing conductivity. Figure 1.12 is a diagram reproduced from Chakraborty et al. 
[2009] depicting the influence of all electrospray parameters on particle ( or fiber) 
diameter: 
• fluid 
• Wrfac:e tension i 
• distance to collector t 
Large pa,tlclelflber 
diameters created with: 
• polymer concentration t 
flbatlfm111mW • molecular weight i 
•flow rate t 
•needledfametert 
• fluid density~) i 
Figure 1.12: Electrospray parameters on particle diameter [14] 
1.5.2 Drug Loading Via Coaxial Electrospraying 
20 
In 2002, Loscertales et al. first introduced the concept of co-axial electrospraying. In 
this, they aligned a smaller needle concentrically within a larger needle [6]. By doing so, 
they demonstrated the ability to create core-shell micro/nano particles that encapsulated 
the inner solution. This work sparked great interest and intense research in the field of 
electrospraying in nanomedicine, particularly for drug delivery systems. 
There are several advantages of electrospraying over other commonly used particle 
preparation techniques (Bangham "film", emulsion, extrusion, ultrasonication, reverse-
phase evaporation, etc.). First, this technique is flexible because it can be used to process 
a variety of inorganic, organic, or polymeric materials [ 5]. Because it is commonly used 
in biological applications (electrospray ionization mass spectrometry, EI-MS), fragile 
biological materials such bovine serum albumin (BSA), insulin, DNA, and cells have 
been sprayed without change or damage to their biological activity [3]. As a technique 
for drug delivery systems, encapsulating pharmaceuticals without harming or disrupting 
their biological properties is a key advantage of electrospraying. Other advantages of 
electrospraying include; high encapsulation efficiency, high drug loading content, and 
uniform distribution in the core. Furthermore, this process does not leave residual 
solvent, and it is easily scalable for high output [14]. All of these features make 
electrospraying a promising preparation method in both the laboratory and clinical 
setting. 
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Chapter 2 
Experimental section 
2.1 Materials 
• Pure cerasome organoalkoxysilane, N-[N-(3-
triethoxysilyl)propylsuccinamoyl]dihexadecylamine, MW 769.6854, was 
obtained from the Zhifei Dai group in China : used as drug carrier vehicle shell 
• Doxorubicin hydrochloride [DXR. HCl. 14-Hydroxydaunomycin. HCl, 
Adriamycin. HCl, MW= 580.0, ~95% (TLC) purity] purchased from Enzo Life 
Sciences via VWR.com: Anti-cancer drug 
• Actoplan High Voltage Power Supply (Model: P030HP1M), Easton, Pa.: used to 
create the electric field. 
• Razel syringe pump (Model R99): used for administering fluids to the needle tip 
to be sprayed. 
• Hotplate Stirrer (Model H400-HS), Biomega Research Products Inc.: used as the 
base on which grounded aluminum foil and the collection dish were placed for all 
experiments. 
• 60 x 15 mm tissue culture dishes, polystyrene nonpyrogenic. VWR: Collection 
dishes for sprayed particles 
• Plastibrand disposable cuvettes (1,5 mL semimicro PMMA- 12,5x12,5x45 mm), 
purchased from UA stores: used for DLS measurements 
• The water used in all experiments was prepared in Millipore purification system, 
resistivity of 19 MOhms 
2.2 Solution Preparation 
2.2.1 Cerasome (15 mg/mL) 
The solution used to create the shell of cerasome vesicles was synthesized by adding pure 
cerasome-forming organotrialkoxysilane lipids to pH3 acid ethanol at a ratio of 1: 10 ( mg 
lipid:µL acid ethanol). The solution was incubated at 25°C for 24 hours to allow for 
hydrolysis of the cerasome lipids before being diluted to a final concentration of 15 
mg/mL (19.5 mM), using pure ethanol. This stock solution was stored at 4°C for at least 
24 additional hours before being used to electrospray cerasome particles. 
22 
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2.2.2 Doxorubicin Hydrochloride 
10 mg Doxorubicin HCl was dissolved in 1 mL deionized water to create a 17 .24 mM 
solution. 10 mg/mL is the maximum solubility of doxorubicin HCl in water. Max 
solubility is important to optimize the drug loading ( drug/lipid) weight ratio. 
2.3 Particle Size and Morphology Measurements 
23 
The particle size and its distribution were measured with a Malvern Zetasizer Nano 
System (Dynamic Light Scattering instrument) at scattering angle and wavelength 
settings used for Liposomes. Z-average (Zavg) is the mean particle diameter based on the 
intensity of light scattered. Polydispersity index (POI) is a measure of the distribution of 
molecular mass in a given sample, and ranges from 0-1. In this study, Zavg and POI will 
be our primary means of determining the size and quality of particles collected with 
different electrospray conditions. A Zavg of 100-300 nm, with a PDI <0.2 is desired. 
This indicates a sample of small particles with a narrow size distribution. 
Particle morphology and size distribution were investigated by scanning electron 
microscopy (SEM) [Hitachi S-4800 UHR FE-SEM] at 15 kV. Samples were sputter 
coated with platinum. 
To confirm accuracy ofDLS measurements, an electrospray was conducted in which 
particles were collected on both an aluminum peg (for SEM) and in the usually collection 
dish of di-water, simultaneously. The core and shell flow rates used for this experiment 
were 27 and 30 µL/min, respectively. A voltage of 11.5 kV was used to create a stable 
Taylor cone. 
2.4 General Experimental Design 
The following experimental set-up was designed based on the standard electrospray set-
up described in literature. Since electrospraying has not yet been used to produce 
cerasomes, no single set-up or parameter values could be adopted and implemented into 
this study. Rather, information and ideas were gathered from a variety of publications. A 
set up that best suited the conditions for this study was assembled. 
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2.4.1 Apparatus 
To prepare core-shell cerasome particles, a coaxial needle arrangement was used. 15 
mg/mL pure cerasome lipids were fed through a capillary tube into an outer 23 gauge 
needle. Milipore di-water was fed through a capillary tube into an inner 27 gauge needle. 
The coaxial needles project downward through an orifice in a large 25"x38"x35" (height 
x width x depth) acrylic chamber used to prevent air contaminants from entering the 
experimental zone. All experiments were conducted within the chamber. A positive 
voltage electrode, from the high voltage power supply, was connected to the outer needle. 
The ground electrode ran from the power supply into the chamber through a small hole at 
the base and was connected to both the aluminum foil and ring electrode (see Figure 2.1, 
2.2). The electric field between the positive and ground electrode connections causes the 
liquid meniscus emerging from the tip of the co-axial needles to draw into a conical 
shape, known as a Taylor cone. When the electrical forces are strong enough to 
overcome the surface tension in the liquid at the tip of the Taylor cone, the charged jet 
breaks into an aerosol spray of fine micro/nanosized particles [3, 14]. The di-water 
encapsulated cerasome particles were collected 11 cm below the needle tip in 6 cm 
diameter tissue culture dish containing 6 mL di-water. The collection dish sits directly on 
a 6 cm diameter circular sheet of grounded aluminum foil. A 6 cm diameter ring 
electrode was also grounded and placed approximately 5 cm below the tip of the needles. 
The idea for using a grounded ring electrode was adopted from Wu et al. [2009] to aid in 
directing the sprayed particles into the collection dish. A hot plate stirrer was used as the 
base for this set-up. A stir bar in the collection dish of di-water was used to continuously 
mix the solution as cerasome particles were collected. This design was intended to 
uniformly disperse the particles as they landed, and prevent a layer of cerasomes from 
accumulating at the surface. The stir bar speed was set to 3 in the range of 0-10. 
Processing parameters, unless otherwise stated, were as follows: applied voltage, 11 ± 1 
kV; Inner needle, 27 gauge; Outer needle, 23 gauge; Core solution flow rate, 18 µL/min; 
Shell solution flow rate, 20 µL/min; distance between nozzle and collection dish, H= 11 
cm; distance between nozzle and ring electrode, 5 cm. 
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particles be created using the coaxial electrospray method?" Assuming they can, the next 
aim of this study is to determine the parameters necessary to do so. The closest related 
work that can assist in getting started is literature on electrospraying ofliposomes [3], 
and publications on the basic properties of cerasomes [ 1, 2, 4, 11]. Although helpful in 
identifying a starting point, the parameters that permit the electrospraying of cerasomes 
(100-300 nm, PDI < 0.2) are highly dependent on solution properties, and will need to be 
identified through experimentation. 
Due to the large number of electrospray parameter variables, it is beyond the scope of this 
work to examine them all. For this study, several variables were set constant. As the first 
aim is to demonstrate that cerasomes can be electrosprayed, experiments were created 
and performed with the intention of finding parameters that will accomplish this goal. 
The analysis of variables only went as far as being able to meet the specific aims. It is 
not the intention, nor a goal of this project to demonstrate and quantify the significance 
that all parameter variables have on the electrospraying process. Answering those types 
of questions will be undoubtedly beneficial in the precise tailoring of particle size, 
improving drug loading capabilities, and increasing efficiency. As such, that work 
constitutes an important and necessary set of future experiments that can build upon the 
groundwork laid in this study. 
2.5.2 Parameter Constants 
Cerasome Concentration 
A concentration of 15 mg/mL was used for all experiments. This would ensure that the 
lipid concentration, which has affects in particle uniformity and morphology, would not 
play a variable role in this study. 
Needle Diameter and Spray Distance 
Co-axial needle diameters and spray distance (needle to ground) are two parameters that 
have been assessed in previous studies. It was determined that neither needle diameter 
nor spray distance play a significant role in controlling particle size [8]. Based on these 
findings, needle diameter and spray distance were held constant for all experiments. The 
co-axial needles used were 27 gauge (inner needle) and 23 gauge ( outer needle). The 
perpendicular distance from needle tip to grounded aluminum foil was 11 cm. The 
grounded ring electrode was used approximately half way in between the needle and 
grounded aluminum foil (~5 cm below the needle tip). 
Core Solution 
With expectations of running dozens of experiments so that parameters could be adjusted 
and fine tuned, it was important to use a core solution that is both readily available and 
inexpensive. Furthermore, with a long term goal of eventually incorporating doxorubicin 
into the cerasomes, it was equally important to consider a core solution that is a solvent 
for doxorubicin. The two important factors for choosing a solvent include cytotoxicity 
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and solubility. As the largest part (by volume) of the core solution, it is essential that this 
solvent have no adverse/toxic side effects to the body. Additionally, as a mechanism to 
improve the drug loading capacity, high solubility is important. Doxorubicin 
hydrochloride is highly soluble in dimethyl sulfoxide (DMSO, 100 mg/mL), poorly in 
ethanol, and fairly soluble in water (10 mg/ml). Of the three, ethanol is least soluble and 
least optimal for in vivo use. Despite lower solubility than DMSO, the availability and 
cost effectiveness of using di-water makes it the optimal choice for this study. 
2.5.S Effect of Electrical Field Strength (Voltage) 
According to literature, the two most important parameters in electrospraying are flow 
rate and electric field strength (applied voltage). Because electrospraying of cerasomes 
has not been previously attempted, a lack of reference literature made it difficult to find 
an appropriate starting value for each. Various electrospray sources were compiled to 
create a possible range of values that may work, based on successful spraying of other 
materials. The operable range was found to be 5-50 µL/min flow rate and 3-20 kV 
voltage. 
To begin experimentation, the effect of voltage on particle size and uniformity was 
determined by keeping flow rate constant. A publication by Chakraborty et al. provides 
an equation for the factors that determine particle diameter (Equation 1.2). In this, size is 
directly proportional to flow rate. Thus, in an attempt to produce smaller particles, the 
flow rate value chosen for this experiment was 10 µL/min. Particle samples were 
collected at four different voltages; 11 kV, 13 kV, 15 kV, and 17 kV. Each collection 
was sampled twice and each sample was scanned twice using DLS, thus totaling 4 scans 
per collection of particles. Results are expressed as the mean Zavg and PDI, ± standard 
deviation (n=4). 
2.5.4 Effect of Flow Rate 
To determine the effect of flow rate alone on particle size, voltage was held constant at 
15 kV while adjustments were made to the speed at which the core and shell solutions 
were administered. Based on results of the varying voltage experiment, it was decided to 
use flow rates of 10, 8 and 6 µL/min. 
* For all three outer flow rates (10, 8, 6 µL/min), an inner flow equal to½ the outer was 
used (5, 4, 3 µL/min, respectively). The effect of this 1:2 (core:shell) flow rate ratio was 
examined in a later experiment, 2.4.7. 
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2.5.5 Effect of Flow Rate (with Stable Taylor Cone) 
The findings of the varying voltage (2.4.3) and varying flow rate (2.4.4) experiments 
presented the need to examine the effect of flow rate on particle size when each flow rate 
had used whatever voltage would create a stable Taylor cone. Three flow rates in the 
range of 5-50 were examined; 5, 20, and 40 µL/min. These represent the outer ( cerasome 
shell solution) flow rate. Core solution (di-water) flow rates were set to 4, 18, and 36 
µL/min, respectively. Before collecting particles, the voltage setting was adjusted 
manually until a visibly stable Taylor cone was observed. Once the voltage required to 
create a stable Taylor cone was found, the experiments were carried out as previously 
described. It was hypothesized, based on findings in literature, that particle size would 
increase with increasing flow rate, and vice versa. Because voltage was adjusted until a 
stable cone was observed, it was additionally believed that there would be no significant 
difference in size distribution (PDI) among the different flow rates. Three independent 
electrospray trials were conducted for each flow rate. Results are presented as the mean 
Zavg and PDI (± standard deviation), n=3. Statistical analysis of significance was based 
on 95% confidence interval (p:::;0.05). 
2.5.6 Down vs. Offset Collection Dish 
It was observed that when voltage is not within the range of 11 ± 1 kV, the Taylor cone 
becomes visibly unstable and gives way to a dripping rather than sprayed solution. To 
separate out and collect only the electrically sprayed particles, the collection dish was 
moved slightly offset from directly below the coaxial needles. An assessment of the 
significance of this offset was done using both a straight down and offset dish together. 
The offset collection dish was placed on the grounded aluminum foil. It was 
hypothesized that the particles being sprayed under the influence of the electric field 
would converge through the ring electrode, towards the grounded foil, and get collected 
in the offset dish. Any large particles that drip from the needles when the cone is 
unstable would be collected in the dish directly below the needles. Based on this 
hypothesis, it was expected that the offset dish would contain smaller particles with a 
lower PDI compared to the downward dish. Size and uniformity of the particles from 
both collection dishes were evaluated in terms of Zavg and the polydispersivity index 
(PDI) obtained from DLS measurements. Statistical analysis of the significance between 
down and offset was based on 95% confidence interval (p:::;.05). 
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2.5. 7 Ratio of Core:Shell Solution Flow Rate, Affect on Particle Size 
It was suggested in a previous study that the ratio of inner (core) to outer (shell) flow rate 
not only plays a role in encapsulation efficiency, but overall particle size as well [5]. To 
test the affect on size, two shell ( cerasome) solution flow rates were examined; 10 and 20 
µL/min. For each, two different core:shell ratios were examined; 1: 1 and 1 :2. Statistical 
analysis of the results (based on Zavg) are used to determine if the difference between 
core and shell solution flow rates play a significant (p::S.05) role in affecting particle size. 
2.5.8 Repeatability 
Once the parameters necessary to create 100-300 nm size cerasome particles with PDI 
<0.2 were determined, the ability to repeatedly produce them was examined. For this, six 
independent electrosprays (n=6) were conducted using the exact same parameters: 
Flow Rate: 18, 20 µL/min ( core, shell) 
Voltage= 11 ± 1 kV 
The size and PDI were measured using DLS. The 6 trial mean of the Zavg and PDI (± 
standard deviation) were calculated and used at the fmal particle size and distribution that 
this study claims to be capable of repeatedly producing. 
2.5.9 Particle Stability 
The particle stability was examined to determine if storage in collection solution (di-
water) had an effect on size or distribution. The surface siloxane network was originally 
introduced onto lipid bilayer structures to make cerasomes more stable than liposomes 
towards both aggregation and membrane destabilization. It is thus expected that 
cerasomes are capable of maintaining their size and PDI during storage conditions. To 
test this, a single collected solution of sprayed cerasome particles was measured for size 
and PDI using DLS over the course of 2 weeks (Day 1, 2, 6, 14). Stability results are 
presented as change in Zavg and PDI over time. 
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Zavg Particle Size vs. Voltage 
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Figure 3.1: Zavg particle size vs. varying voltage (constant flow rate) 
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Figure 3.2: PDI vs. varying voltage (constant flow rate) 
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Zavg Particle Size vs. Flow Rate 
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Figure 3.4: Zavg particle size vs. varying flow rate (constant voltage) 
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Figure 3.5: PDI vs. varying flow rate (constant voltage) 
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Figure 3.9: Down vs. Offset, Zavg particle size - mean and standard 
deviation (Unstable Taylor cone) 
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The offset dish collected smaller particles (306 ± 2 nm) with a narrower size distribution 
(PDI = 0.25 ± 0.04) than the vertical down dish (338 ± 15 nm, PDI = 0.33 ± 0.07). 
Statistical analysis reveals a significant (p = 0.0047) difference in the particles collected 
based on size (Zavg), but not significant difference (p = 0.074) based on PDI . 
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Figure 3.10: Unstable Taylor cone. DLS: Zavg size measurements of particles 
collected; A. straight down, B. offset, and C. shown plotted together. 
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3.4.2 Stable Taylor Cone 
The same experiment was conducted to test the effectiveness of an offset dish, but this 
time using a stable Taylor cone. 
190.4 0.156 208.2 0.278 
198.8 0.167 217 0.248 
217.6 0.158 258.1 0.246 
217.6 0.137 263.7 0.287 
Table 3.6: Down vs. Offset, Stable Taylor cone. 
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Figure 3.12: Stable Taylor cone. DLS: Zavg size measurements of particles 
collected; A. straight down, B. offset, and C. shown plotted together. 
When an appropriate voltage is used to create a stable Taylor cone, the particles being 
produced have a narrow size distribution. Additionally, there is no visible transient drip 
from the needle tips because the electric field is of the exact strength needed to 
completely aerosolize the solution into nanoparticles. These results show there is no 
significant difference between the size of particles collected down (206 ± 14 nm) and 
those collected at an offset (237 ± 28 nm), p = .098, when the cone is stable. 
Interestingly, it was also found that the down dish collected smaller particles with a 
narrower size distribution that the offset dish (p < 0.0001). Taken together, this is 
evidence that an offset collection dish is beneficial when the Taylor cone is unstable, but 
has no benefit over a straight down dish when the electrospray process is stable. 
3.5 Ratio of Core:Shell Flow Rate, Affect on Particle Size 
It was assessed whether the core:shell solution flow rate ratio had any significant effect 
on overall particle size or distribution. Two different ratios; 1: 1 and 1 :2 were tested for 
the three different outer flow rates 10, 20, 30 µL/min. When the outer solution flow rate 
was 10 µL/min, data shows that there is significant difference between particles created 
from a 1: 1 ratio (294 ± 7 nm) and those from a 1 :2 ratio (307 ± 6 nm), p = 0.025. When 
the outer solution flow rate was 20 µL/min, data shows again that there is significant 
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Based on images (A-E, Figure 3.15), the cerasomes collected on the aluminum peg 
during this experiment were in the range of 100-400 nm. Particle morphology appears to 
be an irregular or square-like shape, rather than the expected spherical shape. Also, 
particle density in the viewing area was low, compared to SEM images from other 
cerasome literature. 
3.6.2 DLS Size Comparison with SEM 
PDI width 
251 0.297 136.8 114.2 387.8 
267.6 0.297 145.7 121.9 413.3 
246 0.327 140.6 105.4 386.6 
246.9 0.298 134.7 112.2 381.6 
Average 
Standard Dev. 
Table 3.9: DLS size comparison with SEM 
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Figure 3.16: DLS results for SEM comparison 
The particles collected in di-water during the simultaneous collection on SEM aluminum 
pegs were evaluated using DLS. The Zavg particle size was 253 ± 10 with PDI = .30 ± 
.01. Using PDI width data provided by the DLS measurement, a range oflow-high 
values were calculated for each scan of the sample. An mean (n=4) of the low and high 
values shows the size range of cerasome particles in the solution to be approximately 
100-400. This correlates precisely with what was observed in the SEM images. 
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3. 7 Particle Stability 
A two week stability test was performed to evaluate the effect of hydrated storage 
conditions (particles suspended in water, 4 °C) on both size and PDI. This effect was 
examined on particles created at two different flow rates, 20 and 40 µL/min. The total 
increase in particle size over two weeks was 42 nm and 50 nm, for the 20 and 40 µL/min 
samples respectively. For both samples tested, the PDI varied throughout the two week 
testing time, but neither increased nor decreased on a consistent basis. For the 20 µL/min 
sample, it was measured to be 0.22 (day 1), 0.19 (day 2), 0.17 (day 6), and then 0.20 (by 
day 14). For the 40 µL/min sample, it began at 0.13, went up to 0.18, slightly down to 
0.17, then ended at 0.19 by day 14. Overall, neither sample had a substantial change in 
PDI over the course of two weeks. 
Flow Rate 
[µL/min] 
20 
40 
Table 3.10: Particle stability in collection solution 
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Chapter 4 
Discussion 
The field of nanomedicine and drug delivery systems are in need of both a superior 
carrier vehicle and preparation technique than what is currently being used. Liposomes 
have demonstrated success in both the lab and clinic, and are currently the most widely 
used drug delivery vehicle. Despite wonderful biocompatibility and many great 
advantages, liposome suffer from an inherently weak membrane stability. Exposure to 
conditions of low (or high) pH, surfactants, or mechanical stress cause them to destabilize 
and consequently release their drug. Additionally, liposomes have a tendency to 
aggregate and fuse with other liposomes, which increases their size and facilitates 
clearance from the body. Both premature drug release and short circulation times limit 
the therapeutic effectiveness of liposomes. Recently, a novel organic-inorganic hybrid 
known as a "cerasome," for its siloxane surface network, has been developed. Due to the 
improved membrane strength, cerasomes have demonstrated superior morphological 
stability (against destabilization and aggregation) over liposomes. Additionally, 
cerasomes have a slower and more controlled drug release profile, which enhances their 
therapeutic effect. 
Despite the creation of a superior liposome-like drug delivery vehicle, there remains a 
lack of an efficient and effective preparation technique. Laboratory methods, such as the 
film method, sol-gel/self assembly, reverse phase evaporation, freeze/thaw, etc. are 
commonly used to prepare liposomal drug vesicles. The problem with these methods is 
that they are multi-step, lengthy, and often complication processes that produce less than 
idea particles (i.e. polydisperse size distribution, low encapsulation efficiency, and low 
drug loading content). Recently, a one-step, facile technique known as coaxial 
electrospraying has emerged. Having demonstrated the ability to address and correct 
these issues makes electrospraying a very promising technique. While electrospraying 
has shown great success using standard liposome lipids and biodegradable polymer 
materials, it has never yet been used to create core-shell cerasome particles. The 
combination of using a more superior vesicle material with a more efficient preparation 
technique is an exciting new area of research. This study sets out to demonstrate that the 
coaxial electrospraying technique can successfully produce core-shell cerasome vesicles 
of the optimal size (100-300 nm) and distribution (PDI<0.2) for drug delivery 
applications. 
Prior to beginning experiments, an extensive literature review uncovered many of the 
important parameters and their affect on the electrospraying process. Based on this 
47 
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review, an experimental plan was devised. It was hypothesized that given a solution of 
constant concentration, conductivity, viscosity, and surface tension, both flow rate and 
voltage could be varied to tailor particle size. Specifically, there would be a particular 
voltage that would create an electric field of appropriate strength to aerosolize the 
solution. Once this was found, particle size could be reduced to within 100-300 nm by 
decreasing the flow rate. Upon experimentation, this hypothesis was found to be only 
true in part. There was a specific voltage that stabilized the Taylor cone (11 ± lkV), but 
varying flow rate from 5-40 µL/min showed no significant affect on particle size. All 
flow rates within this range produced particles between 190-230 nm, with PDI < 0.2. 
Effect of Electrical Field Strength (Voltage) 
To determined the sole effect of voltage on particle size, all parameters were held 
constant. At a flow rate of 10 µL/min, it was found that 11 kV produced particles with 
the smallest size and distribution. Figure 3.3 shows photographs of the Taylor cone as it 
forms, stabilizes, and then destabilizes throughout the range of7-15 kV. At 9 kV, the 
cone began to form. As voltage increased past 12 kV, the cone destabilized and particles 
became increasingly larger and more polydisperse. The most significant finding from 
this experiment was that the voltage that produced the best particles was also the one that 
stabilized the Taylor cone. Comparing visual images of the cone formation with the 
Zavg and PDI data, there is a clear relationship between a stable cone and high quality 
particles. This experiment solidified the importance of the voltage parameter in the 
electrospray process. 
Effect of Flow Rate 
Looking at the results of the previous experiments, it was questioned whether flow rate 
would have the same effect. To test this, voltage was held constant at 15 kV because this 
voltage does not create a stable Taylor cone. When 15 kV was used with a flow rate of 
10 µL/min in the previous experiments, it produced large, polydisperse particles. This 
particular experiment would examine if a 15 kV electric field could be made to produce 
small, narrowly distributed particles solely by adjusting the flow rate. If the hypothesis 
that only one specific voltage would work for this particular solution, no amount of 
variation to flow rate could make 15 kV produce a stable Taylor cone. It was found that 
as flow rate was decreased from 10 to 6 µL/min, the electrospray process became slightly 
more stable, noted by a decrease in both particle size and PDI. Despite an improvement 
in particle quality, the Taylor cone never emerged as stable. The effect of changing flow 
rate (with constant voltage) did not have the same effect on improving particle quality as 
did changing voltage (with constant flow rate). This finding points towards voltage being 
the key factor in Taylor cone stability and thus particle size uniformity. Because of this 
data, a new experimentation was designed in an attempt to produce particles of ideal drug 
delivery size (200 nm) and distribution (<0.2) by varying flow rate, but this time using 
whatever voltage would create a stable Taylor cone for each flow rate. 
Effect of Flow Rate (with Stahle Taylor Cone) 
It was decided to test the affect of flow rate on particle size and distribution when voltage 
' ( 
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was adjusted to create a stable Taylor cone for each flow rate examined. Figure 3.6 
shows photographs of the Taylor cone as voltage is adjusted between 8 and 12 kV. A 
well defined and stable cone emerges at 10 and recedes at 12 kV. Interestingly, this was 
the same for all three flow rates examined; 5, 20, 40 µL/min (photographs not shown for 
5 and 40 µL/min). Figure 3.3, which showed the Taylor cone stability over the range of 
7-15 kV using a flow rate= 10 µL/min, also exhibits a stable cone in this exact same 
range. It is thus concluded that for the particular cersasome solution properties and 
concentration being used, all flow rates between 5-40 µL/min require a voltage of 11 ± 1 
kV to form a stable Taylor cone. This finding supports the hypothesis that there would 
be one specific voltage that permits a stable electrospray, but refutes the notion that flow 
rate could tailor particle size. As for the slight (±1 kV) variation in required voltage, it is 
believed that minor, unintended differences in the preparation of the cerasome solution 
slightly alter its physical properties. Factors such as precise concentration, hydrolyzation 
time, and time in storage may all contribute to the varying physical properties of the 
solution between experiments. 
Identifying the voltage required to create a stable electrospray process is vital to the 
successful production of small, narrowly distributed particles. Once this required voltage 
value was established to be 11 ± 1 kV, it was possible to go forth and test the affects of 
varying flow rate on particle size. It was expected, based on literature, that varying flow 
would have a significant affect in controlling particle size. The findings from this study 
were surprising in that they did not support this. However, the goal of creating 200 nm 
sized particles (<0.2 PDI) was achieved regardless. All three flow rates (5, 20, and 40 
µL/min) created particles in the range of 190-230 nm with less than 0.2 PDI. Table 3.4 
shows the p-value significance between each of the three flow rates. A p-value of .046 
between the 20 and 40 µL/min flow rates is the only one that shows a barely "significant" 
difference (95% confidence). Despite this, varying flow rate shows no form of a usable 
pattern for particle tailoring. Based on the PDI, 5 µL/min produced the most best 
particles (0.08 ±0.03), followed by 40 µL/min (0.14 ±0.01) and then 20 µL/min (0.16 
±0.03). Based on average and standard deviation of the Zavg size measurements, the 
same pattern was observed. 5 µL/min created the overall smallest particles. Taking 
average size, standard deviation, and PDI of the data collected into consideration, it is 
concluded that there is no significant size-related affect of varying the flow rate between 
5 -40 µL/min, which represents the operable range for electrospraying cerasomes. 
A possible explanation for this deviation from accepting findings could be as simple as 
the need for more data. Because of the overwhelming evidence that there should be a 
proportional relationship between the flow rate and size, it would be beneficial to re-visit 
these experiments in the future. A larger range of flow rates (beyond 5-40 µL/min) may 
bring forth a pattern not observed in these experiments. 
Despite inconclusive results for the affect of flow rate on particle size, the goal of 
creating 200 nm sized particles with <0.2 PDI was accomplished using all three flow 
rates. 5 and 20 µL/min created the smallest particles with lowest PDI, and no significant 
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When an unstable Taylor cone was intentionally introduced, the offset dish collected both 
smaller particles (306 ± 2 nm) with a narrower size distribution (PDI = 0.25 ± 0.04) than 
the vertical down dish (338 ± 15 nm, PDI = 0.33 ± 0.07), as hypothesized. Statistical 
analysis reveals a significant (p = 0.0047) difference in the particles collected based on 
size (Zavg), but not significant difference (p = 0.074) based on PDI. These results show 
the benefit of using an offset when the electrospray process is not completely stable. 
However, when a stable Taylor cone was used, there was no significant difference 
between the size of particles collected in the down vs. offset dish (p = .098). The down 
dish did, however, collect a smaller average size and standard deviation of particles 
(206±14 nm vs. 237±28 nm). In addition, the down dish had a much lower PDI than the 
offset dish (p<.0001). This data, taken together, shows that when the cone is stable, there 
is no benefit of using an offset collection dish. However, because brief periods of 
instability are both likely and unpredictable, the offset dish set-up is a useful safety 
mechanism to improve consistency between experiments. For this reason, a slight offset 
was implemented for all subsequent experiments. 
Ratio of Core:Shell Solution Flow Rate, Effect on Particle Size 
The results of these experiments showed that there is a significant difference between the 
size of particles created using a 1: 1 and 1 :2 ( core:shell) flow rate ratio. For the three 
different flow rates examined (10, 20, 30 µL/min), the ratio of 1 :2 (slower core solution 
rate) created slightly larger particles. 
Based on this data, it is recommended that the core solution flow rate be only slightly less 
(a few µL/min) than the shell solution. This reason for this is; a slower core flow rate 
promotes better encapsulation. But, since a core rate twice as slow as the shell rate (1 :2) 
begins to increase particle size compared to a ratio of 1: 1, it is best to use a core flow rate 
close to (but less than) that of the shell solution flow rate for keeping particles small. 
According to Chakroborty et al. [2009], flow rate ratios between the core and shell 
solutions have profound effects on the particles produced. For flow rate ratios less than 
1 :2, there is insufficient shell solution to encapsulate the core solution. For increased 
shell flow rates, i.e. ratios between 1 :2 and 1 :3, there is only occasional encapsulation of 
the core solution. Ratios between 1 :3 and 1 :6 consistently yield stable core/shell Taylor 
cones. Any further increase, i.e. 1 :7 to 1: 10 does not affect cone stability, but begins to 
reduce encapsulation efficiency of the core solution. These findings were made using 
polymer shell and BSA core electrosprun fibers. While there may be some universally 
consistent pattern for the affect of flow rate ratio, this has not been verified specifically 
for electrospraying other materials, such as cerasomes. It would be interesting for future 
studies to examine a larger range of flow rate ratios (i.e. 1: 1 - 1: 10) for their affect on 
size. Additionally, further experimentation is needed to identify the best flow rate ratio 
for optimizing encapsulation efficiency. It is likely that there will need to be a 
compromise between the best ratio for reducing size and that for increasing encapsulation 
efficiency. 
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Repeatability 
Using the parameters identified through experimentation, cerasome particles of average 
size 217 ± 17 nm (PDl=.19 ± .05) can be repeatedly produced using the electrospray 
process. This size is optimal for both body clearance evasion and tumor vasculature 
penetration. Repeatability is an important factor if the coaxial electrospray method for 
core-shell particle production is to ever have widespread laboratory or clinical 
acceptance. 
53 
SEM images were taken to both observe the particle morphology and determine the 
accuracy ofDLS size and distribution measurements. The sizes measured for one 
particular sample under DLS (Zavg: 253 ± 10 nm, PDI = 0.30 ± .01) were confirmed by 
SEM images. Both DLS and SEM show a distribution of approximately 100-400 nm. 
The morphology, however, was not as expected. Rather than smooth, spherical particles, 
the cerasomes exhibit a flattened, irregular and often square-like shape. This could be a 
result of core solution (di-water) evaporation or leakage from the vesicles prior to SEM 
anaylsis. As such, the particles may deflate and flatten out on the aluminum peg surface. 
Another possible explanation is that vacuum conditions and the platinum sputter coating 
flattened the particles. To fully understand the reason for this observed morphology, 
further investigation will be necessary, 
The major difference between SEM images of this study and others referenced is the 
density of particles in the viewing area. In our images, there is a very low density of 
particles. This could be because the aluminum peg was not grounded during the 
collection process. It was held suspended above the collection dish, so that particles 
could passively land on the surface as they moved toward the grounded aluminum foil. 
Because it the peg was not grounded, however, it is suspected that the particles moved 
around the peg to land in the dish. Only a small fraction of the particles were collected 
on the surface. 
Particle Stability 
After creating cerasome particles, there was often a short wait period before DLS access 
became available. This wait ranged from 1-7 days. During this time, particle solutions 
were kept suspended in their collected, hydrated state in 4°C refrigeration. To examine 
the affect of this storage time on particle size, a two week stability test was performed. 
Two particle samples were created, one using 20 µL/min flow rate, the other 40 µL/min. 
The results show that over two weeks, the particle size increased by 42 and 50 nm, 
respectively. The solution prepared at 20 µL/min had a decrease in PDI from 0.22 to 
0.20 at two weeks. The solution prepared at 40 µL/min had an increase in PDI from 0.13 
to 0.19 at two weeks. This conflicting data points toward an insignificant change in PDI 
over the two weeks. Because size increased independent of size distribution (PDI), we 
suggest that it is due to absorption of water, and thus swelling of the particles. Since the 
particle are loaded with di-water and also suspended in a hydrated storage condition of 
di-water, it is plausible that absorption has caused the gradual size increase. It is not 
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believed that the size increase is due to aggregation or fusion of particles. If this were the 
case, we would expect to see a large increase in size distribution (PDI) as some particles 
would be doubling or tripling in size as others remain unchanged. An unchanged PDI 
makes this explanation unlikely. The information gathered in this experiment is 
significant because it provides a linear reference to how much the particles can be 
expected to expand at any given time (up to 14 days). By fitting a trend line to the data, it 
provides a way to standardize the size measurement of particles that are obtained after 
different lengths of time in storage. See Figure 4.2. 
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Figure 4.2: 14 day particle stability (with linear trend lines) 
Future work should run this storage stability experiment for a longer period of time to see 
if the pattern continues or eventually plateaus. If the size increase is due to swelling, 
there should be a point where the particles reach maximum expansion and plateau. A 
long term experiment would also provide important information on how long cerasomes 
remain stable in storage conditions, or at what point they being to aggregate or 
destabilize. This information has important clinical implications. 
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Additional Findings 
The following discussion is based on the results of experiments not mentioned in the 
results section of this study. 
Solution Preparation 
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Before electrospraying and collection particles, the cerasome lipids were hydrolyzed in 
pH3 ethanol for 24 hours, then given an additional 24 hours incubation period to allow 
for a complete surface siloxane network formation. When this 24 hour time period was 
not permitted, and electrosprays were conducted immediately after hydrolyzation, the 
particles produced had very large Zavg size and size distribution (PDI) measurements. 
The DLS "Expert Advice" feature indicates that the solution is not stable, and that 
particles may be aggregating. This makes sense, given that the additional wait time is for 
the siloxane network to completely form, which then prevents aggregation. Figure 1.10 
shows support for why post-processing incubation for an additional 24 hours helps to 
strengthen the vesicle against destabilization. Furthermore, Cao et al. [2010] report that 
freshly prepared cerasomes were stable in alkaline condition (supported by the zeta 
potential chart), but were sensitive to acid. The inorganic siloxane network was not well 
developed on the surface of newly prepared cerasomes. But, after 24 hours, cerasomes 
showed remarkable morphological resistance toward both acidic and alkaline solution. 
These findings in literature support our results. 
Effect of Radial Distance on Particle Size 
Radial distance refers to the distance extending outward in any direction from a point 
directly below the needles. Particles ejected from the needle tip travel in a conical shape 
towards the ground. Although no previous studies mention radial distance as a factor, it 
was hypothesized, based on results showing that an offset was beneficial, that if particles 
being sprayed are polydisperse, they will spray radially according to their size and mass. 
Specifically, large particles will spray closer to directly down, whereas the smaller and 
lighter particles will travel further from the needles. If this were true, it would then be 
possible to collect the desired sized particles by placing the collection dish a certain radial 
distance from the needle. The exact distance would be determined through 
experimentation, and would also likely vary with other parameters such as flow rate and 
or voltage. 
To test this hypothesis, a target dish was created using four different size tissue culture 
dishes aligned concentrically (Figure 4.3). This created thin circular zones to collect 
particles traveling different radial distances. The center zone covered radial distance 0-
0 .5 cm. The second zone covered radial distance from 0.5 to 2.5 cm. The third zone 
covered distance from 2.5 cm to 4 cm. The outermost zone collected particles traveling 4 
cm to 7 cm. Two independent trials were conducted using the target dish collection set-
up. In both cases, there was no evidence to support the hypothesis of radial distance 
effecting particle size. The particles collected in the zones had varying sizes and PD Is 
with no particular consistency. Additionally, the two trials showed no common result 
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4.1 Future Work 
This study was successful in accomplishing both aims laid out in section 1.1 - Specific 
Aims. Briefly, these were to (1) demonstrate that the electrospraying technique is capable 
of producing cerasome vesicles, and (2) identify the parameters required to produce 
particles of optimal size (100-300 nm) and distribution (PDI<0.2) to be effective drug 
delivery vehicles. Both of these aims were met, and yet the work of this study is only 
laying the groundwork for the future of electrospraying cerasomes. Additional work that 
can build upon this study include, but is not limited to; 
• Using cryo-SEM (or TEM) to visualize the core-shell structure of the cerasome 
vesicles. Our study used SEM to observe overall morphology and size 
distribution, but visual evidence of the core-shell structure is also needed. 
• Extending the storage stability experiment for a longer period of time. 
• Alter the cerasome-forming organotrialoxysilane lipid concentration to less than 
and greater than 15 mg/mL while examining the effect on electrospray parameters 
and particle size ( or distribution) 
• Encapsulate doxorubicin drug into the core of cerasome particles. 
o Verify that drug loading does not affect particle size 
o Visualize morphology and confirm size distribution under SEM 
o Use contrast agent to visualize drug encapsulation in the core (under cryo-
SEM or TEM) 
o Measure encapsulation efficiency (E.E.) 
■ Alter parameters (i.e. flow rate ratio) to improve E.E. 
■ Measure drug loading content 
■ Improve drug:lipid ratio by exploiting solubility of the drug. If 
max solubility in water is not enough, try DMSO. Doxorubicin is 
more soluble in DMSO (100 mg/mL) than water (10 mg/mL). 
o Show the drug release profile of doxorubicin loaded cerasomes under 
various pH and surfactant (TX-100, ethanol) conditions. 
■ Adjust lipid concentration to improve membrane permeability (i.e. 
drug release profile) 
■ Include membrane destabilizing modalities to create "trigger-able" 
drug release 
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Appendix 
A. Liposomal drugs 
A.1 FDA-approved liposomal drugs 
Dnc--C•Rllu.Y I~upt ~-
Maiqib-V mclirin sulfate lipo,omes injectkm.: Vmcristine-e"ICapsulated Tiutment of adult patirtnls witlucute l)lfflplldilastic 245 
liposo:me• in a lipid hila~r of sphiri&Pm:Y'!lin (Hana Biascirt=•s) leukemia. 
D.uno'Xome: DllmlOJUhicincitrate•liposo:me utj,,ction (NeXstar Adv~ HIV-associated Kaposi's sarcomailrfint- 246 
~ticals) lw use 
AmBiso:meG): Lipid-hti<!d fbJl'IIU.latiom, in:ludwg liposomal T1ut:ment dil:rngal imoctionan:I vucenlleishmuiasis 247,248 
ut1pl»toricin B (Tujis-a Health:ai,e) 
DoxilG), caylex: PEGylatod liposomal loaded withdolQ)iuhicin(PLD) TNatm,,ntd:mewta.tichieuh:ancer, advur:edovuian 249-252 
(Ben Vemi. Laboratoms for Johmon& Johnson) can:ei; multiple m)lf!loma, an:! AIDS -111bted Kaposi's 
u.n:oma 
Ampm::il: Lipid form r:£ amph>teoonB stahilimd with cldesteryl 
sulfa.to (Sama:ritmP:humaceuticals) 
ABELCE'I"l: Amph:itericinB lipid conq,lexed with lwophasph>lip:ids 
(DMOC:DM:ro, 7:3 molanatio) ina l:l diug-to-lipid =larntio (The 
Lipasome Co~) 
Amphocilhirtds to lipopmtew and ergosterolincell 
m,,ml,rane; of iril!ctwg tulilP; also il!dicaled i>r the 
t111atm,,ntr:£invuiw aspeigillasis and leishmanwis 
ABELCET® CONW of am,photericin B, a polyem, 
~al anti>iotic for invasive fungal hlt•tmelllt 
253,254 
255 
Depocyt'": Liposo:mal cyt.a:r..b:im or liposo:mal Ara,.C ai,e mti:met..bolite DepoCyt is a su,tm,ed ielease fi>mmlationofthe 256 
cyt.a:r..b :im, e"ICap:ru.lated inlO i:mltiwsiculai lipid-Ii ased particles (El'lmn chemotltarapwtic agent cytuabine, used for the 
Ph.um.aceutic.us) heat:me:llfdpatirtnu wdh lymphomatous menrg:itis 
Chart reproduced from Puri et al. [2009] 
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APPENDIX 
A.2 Liposomal drugs in clinical trials 
Li.posomal-am.amycin s•mi-s ynthetic 
doxoiubicin analog: Atum:!ity,::in inmcalates 
int.>DNA mi inhibits topoisomoue II 
(Amn.ex Plw:maceutic~) 
Lipq,latin: A 1111w cisplatin-tncaPfuu.led 
liposome composed ofDFro,soy 
ph:>sphatidyl choline (SPC-3), ch:>les le:rol, mi 
mPEG2000-DS PE, designed to n,duc:e 
cispla.tin toxicitws w ithmt wduc:~ eff'icacy 
(HBio) 
NX 211 (liposomal brtotecan): Lipc»omal 
formulation of the lo.rtotecm a bpoisomerue 
I irihib ibr (Gilead mi G laxo) 
Liposom.al vi:rr:ristine (ONCO-TCS"): 
Villl:ristine e:rr:apnilated inli.posomes 
composed of sphi~om)l'lllin ani cholesterol 
(INEX Phum.acw.tic~) 
DoxOlllbicin HCL liposome foriijection: 
Non-PEGylaled liposom.al doxoiubicin 
Myo::et made by Emon Phum.acetical; for 
Cephelon in Europe mi fer SopluniCll'l 
Therapeutics in the Uni.led St.ates mi Canada 
VenmsTM: ProstaglmiinEl liposomes (The 
Li.posome Col'l.'IPUW') 
Thei:moDoxTM: Ly,olipid thermallynnsiti.w 
liposomes are neat-activated liposom.al 
tncapsula.tionofd-,rubicin(Cel;ion 
Co.ipa:ation) 
Protein-stabilized liposo:me encapsuu.tionof 
actin dNg Doc:eta.xel(ATI-1123): Liposo:me 
pioduetmade ina s~le step anl. e:rr:apsulales 
Doceta.xel a c:linieallywell-established mti-
mibtic cliemotherapy medication (Aaya) 
ACl.11111 myeloid mi lymphoid 
lw.lremia (dzu€-n,si.st.ant mmors) 
5'1111:tw 
Pl:weillI 
Can:il!Oma of the liead ani neck, Pl:we II clinical trial mi oo.e phase III 
p;m:reati.c canc&r, ani contim~ in Mn-inferiority clinical slll.dy 
advanced blll!ast cancer mi 
gastrointestinal ca:rr:e:is 
Advmu:ed orncumnt O'l'anm Pl:we II 
epithelial cance1 
T•atment ofnlapsed agg:111ssiw, Pivot.al phase llllII 
mn-Hodc;kin's lym,ph:>mamiother 
cancers 
Tieatment i:>r patient! with stage II 
orlliinY'uiwbnutca:rr:ermiwitk 
tesb sllowiJig montexpnu~ of 
lu-epidetmal gl'OW'th factor 
n,ceptor 2; Myoeet@is approved in 
Europe ani Canada fortn,atment of 
met.a.static bnut cancer 
Pntteatment of .:ute n,spi:ratoiy 
disttess synd]ome 
'I'h!rmoDoxTM cm be used as 
tteatment fer liepabcello.lar 
carcinoma (prinwy liver cancer) 
ani teeUmntcnestwallbnast 
cancer 
Doceta.xel(trade -Tuoten,) is 
used mainly for the tn,atmelll of 
bteu t, ova:rim, mi l!Ol:l:-S mall cell 
lo.~cancer 
Pivot.al phase llI global tec;i.strational 
trial i:>r tteatment ofH ER2-pos itivt 
metastatic bnut cmcer 
Pl:we III clinical trial 
Pl:weIII 
P•-clinical studies b FDA phase I 
clinical trial 
Chart reproduced from Puri et al. [2009] 
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